Fennec Pharmaceuticals financials
$10.80−1.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.9M | $15.1M | $13.8M | $12.5M | $9.7M | $8.8M | $7.9M | $7.0M | $7.3M | $25.4M | $9.7M | $6.5M |
| Gross profit | $17.2M | $14.5M | $12.0M | $11.8M | $8.7M | $8.4M | $7.3M | $5.6M | $6.7M | $24.8M | $9.1M | $6.2M |
| Gross margin | 96.0% | 96.2% | 87.2% | 94.7% | 90.0% | 95.7% | 91.6% | 80.5% | 91.6% | 97.8% | 93.0% | 94.9% |
| Operating income | $1.7M | -$119.0K | -$2.6M | -$189.0K | -$2.7M | -$808.0K | -$934.0K | -$5.2M | -$5.0M | $13.7M | -$1.8M | -$1.0M |
| Net income | $2.0M | $201.0K | -$4.8M | -$638.0K | -$3.2M | -$1.2M | -$2.0M | -$5.7M | -$5.6M | $12.8M | -$2.7M | -$1.9M |
| Net margin | 11.0% | 1.3% | −34.7% | −5.1% | −32.7% | −13.3% | −25.0% | −82.2% | −76.5% | 50.6% | −27.6% | −28.7% |
| Diluted EPS | $0.05 | $0.01 | $-0.15 | $-0.02 | $-0.11 | $-0.04 | $-0.08 | $-0.21 | $-0.20 | $0.41 | $-0.10 | $-0.07 |
| EBITDA | $1.7M | -$119.0K | -$2.6M | -$189.0K | -$2.7M | -$808.0K | -$934.0K | -$5.2M | -$5.8M | $14.5M | -$1.8M | -$1.0M |
| Operating cash flow | $50.0K | $2.4M | -$6.0M | $1.5M | -$3.7M | -$4.3M | -$1.5M | -$2.2M | -$8.4M | $39.0M | -$4.9M | -$2.8M |
| Free cash flow | $50.0K | $2.4M | -$6.0M | $1.5M | -$3.7M | -$4.3M | -$1.5M | -$2.2M | -$8.4M | $39.0M | -$4.9M | -$2.8M |
| Diluted shares | 36.4M | 35.5M | 31.2M | 27.9M | 27.7M | 27.6M | 23.4M | 27.4M | 27.3M | 31.1M | 26.7M | 26.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.2M | $40.2M | $36.8M | $21.9M | $18.7M | $22.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $19.4M | $19.4M | $18.2M |
| Total assets | $75.8M | $71.8M | $70.6M | $49.3M | $44.9M | $46.4M |
| Total liabilities | $33.3M | $34.1M | $35.1M | $53.8M | $52.3M | $52.3M |
| Shareholders' equity | $42.4M | $37.7M | $35.5M | -$4.5M | -$7.5M | -$5.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology